Antileukotriene drugs in complex treatment of recurrent laryngotracheitis in children with allergic diseases for prevention of lower respiratory airways obstruction

Abstract

We studied the possibility of prescribing antileukotriene drugs in children with recurrent laryngotracheitis for the prevention of bronchial obstruction. Examined 120 children (71 boys and 49 girls) with recurrent laryngotracheitis at the age of 3–9 years at the beginning of observation. Allergic diseases (allergic rhinitis, atopic dermatitis) were diagnosed in 80 children, divided into groups Ia and II of 40 people, respectively, before inclusion in the study. The level of total serum IgE in children ranged from 50 to 2000 IU/ml, polysensitization was noted (to household, pollen, fungal allergens). Patients of the I-st group received therapy according to the standards of treatment for obstructive laryngotracheitis. Group II, consisting of 40 patients with allergic deseases, additionally received 2 months montelukast courses trice a year, in periods without episodes of recurrent laryngotracheitis. For 3 years of follow-up, it was possible to determine groups of children with recurrent laryngotracheitis in combination with repeated bronchitis with obstructive component (50%), some of patients were diagnosed with mild intermittent bronchial asthma (21,9%). The formation of bronchial asthma was observed in children with allergic diseases who did not receive montelukast in 32% of patients, and in 15% of children who received montelukast, the difference is reliable. Prescription of montelukast for children with recurrent laryngotracheitis in combination with allergic diseases, family history of atopy, and the monitoring of an allergist are recommended.

Keywords

• atopic sensitization
• allergic diagnosis
• reccurent laryngotracheitis
• bronchial asthma
• antileukotriene drugs